Finding the Achilles heel of cancer

March 28, 2018, Instituto Gulbenkian de Ciencia
Finding the Achilles heel of cancer
Healthy cells (left image) display four centrioles, a normal number (in yellow). On the contrary, breast cancer cells (triple negative) have extra centrioles (here 16, right image). Credit: Gaëlle Marteil, IGC.

A research team led by Monica Bettencourt Dias, from Instituto Gulbenkian de Ciencia (IGC, Portugal), has discovered important features of cancer cells that may help clinicians fighting cancer. The researchers observed that the number and size of tiny cellular structures called centrioles are increased in the most aggressive sub-types of cancer. This study will be published in Nature Communications on the 28th of March.

Some tumours are more aggressive and resistant to chemotherapy than others. Clinicians are eager to find novel diagnostic, prognostic and treatment tools that allow them to predict outcomes and treat patients in a more personalised way. The study may contribute to this process.

About 100 times smaller than the cross section of a hair, centrioles have been called the cell's "brain," as they play crucial roles in cell multiplication, movement and communication. Their number and size are highly controlled in . Since their discovery more than a century ago, it has been proposed that an abnormal increase in the number of these structures may induce cancer..

Bettencourt-Dias's team investigated the incidence of centriole abnormalities in human cancer cells. The researchers thoroughly analysed a panel of 60 human cancer lines originated from 9 distinct tissues. Their results reveal that often have extra and longer centrioles, which are absent in normal cells. Importantly, the research team observed that supernumerary centrioles are more prevalent in aggressive and . Also, the team discovered that longer centrioles are excessively active, which perturbs cell division and could favour cancer formation.

"Our data confirm that deregulated number and size of centrioles inside cells is associated with malignant features. This finding may help establishing centriole properties as a way of classifying tumours in order to establish prognosis and predict treatment response," says Gaelle Marteil, first author of this study and researcher at Bettencourt-Dias laboratory.

What is the next step? "The cell lines that we analysed are already well characterized in terms of genetic changes and resistance to therapeutics. We are pursuing our studies in collaboration with Nuno Barbosa-Morais' team at Instituto de Medicina Molecular, in Lisbon, and Joana Paredes at I3S, in Porto, to explore new mechanisms and therapeutics that could target in cancer," adds Monica Bettencourt-Dias.

Explore further: New discovery may enhance chemotherapy's efficiency against leukaemia

More information: Marteil, G., Guerrero, A., Vieira, A.F., de Almeida, B.P., Machado, P., Mendonça, S., Mesquita, M., Vilarreal, B., Fonseca, I., Francia, M.E., Dores, K., Martins, N.P., Jana, S.C., Tranfield, E.M., Barbosa-Morais, N.L., Paredes, J., Pellman, D., Godinho, S.A., Bettencourt-Dias, M. (2018) Over-elongation of Centrioles in Cancer Promotes Centriole Amplification and Chromosome Missegregation. Nature Communications. DOI: 10.1038/s41467-018-03641-x

Related Stories

New discovery may enhance chemotherapy's efficiency against leukaemia

December 13, 2017
In patients with acute myeloid leukaemia, cancer cells resist the effects of chemotherapy, many times resulting in disease recurrence and ultimately death. Researchers from Instituto de Medicina Molecular (iMM) João Lobo ...

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.